M/19/046 – Recipharm/Consort

Transaction details

The proposed acquisition whereby Recipharm Holdings Limited will acquire sole control of Consort Medical Plc has been cleared by the Competition and Consumer Protection Commission.

Notification date Decision date
Friday December 20, 2019 Tuesday, January 28, 2020
Parties Involved Business activities
Recipharm Holdings Limited

Recipharm Holdings Limited is a wholly owned subsidiary of the Recipharm Group.

Recipharm Group is a global contract development and manufacturing organisation (CDMO). It is a global provider of drug development and manufacturing services to the pharmaceutical industry.

Recipharm Group offers manufacturing services for finished dose pharmaceuticals (FDPs) and active pharmaceutical ingredients (APIs).

Recipharm Group has no manufacturing or development facilities in the State. However, it does have sales to pharmaceutical companies based in the State.

Consort Medical Plc

Consort is a global CDMO providing drug formulation and manufacture (both FDPs and APIs) as well as drug delivery device development and manufacture to pharmaceutical partners globally and in the State.

Economic sector Media merger
Pharmaceuticals No
Submissions from third parties due by:
Phase 1 Phase 2
Tuesday, January 7, 2020
Current status: Completed
Cleared (Phase 1)
Authorised Officer Assigned Contact Details
Barry O'Donnell

Email: barryodonnell@ccpc.ie
Phone: 01 470 3696

Craig Whelan

Email: craigwhelan@ccpc.ie
Phone: 01 402 5504

Media enquiries: communications@ccpc.ie

Return to Merger Notifications

Join our mailing list

Sign up to receive the latest information about mergers:



Read our privacy statement

Haven’t found what you’re looking for?